Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase 4
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: Highly active antiretroviral treatment (HAART)
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47
- Registration Number
- NCT00487188
A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 280
- Registration Number
- NCT00484939
The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Pegylated-interferon Alfa-2a
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 236
- Registration Number
- NCT00483938
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.
Phase 2
Withdrawn
- Conditions
- PainNeoplasm MetastasisBone Neoplasm
- Interventions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00478270
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Phase 2
Completed
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 122
- Registration Number
- NCT00475423
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: Taxane (docetaxel or paclitaxel)
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT00475670
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 14
- Registration Number
- NCT00475072
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 27
- Registration Number
- NCT00474955
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Phase 2
Completed
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Drug: First line chemotherapy
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT00472420
- Locations
- 🇭🇺
University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology, Debrecen, Hungary
🇭🇺Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology, Kaposvar, Hungary
🇭🇺Zala Megyei Korhaz; Ii. Belgyogyaszat, Zalaegerszeg, Hungary
Postoperative Canadian Oral Anticoagulation Self-management (Post-COAGS) Trial
Not Applicable
Withdrawn
- Conditions
- Cardiovascular Abnormalities
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00468702
© Copyright 2025. All Rights Reserved by MedPath